[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. França CM, Caran EM, Alves MT, Barreto AD, Lopes NN: Rhabdomyosarcoma of the oral tissues--two new cases and literature review. Med Oral Patol Oral Cir Bucal; 2006 Mar;11(2):E136-40
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma of the oral tissues--two new cases and literature review.
  • Rhabdomyosarcoma (RMS) is a malignant soft tissue neoplasm consisting of cells derived from the primitive mesenchyme that exhibit a profound tendency to myogenesis.
  • About 35% of RMS arises in the head and neck, being classified as parameningeal and non-orbital non-parameningeal forms.
  • The use of contemporary, multi-agent chemotherapy, radiotherapy, and surgery has made treatment of the disseminated disease possible, and has significantly improved overall survival from 25% in 1970 to 70% in 1991.
  • Before final diagnosis, both cases were previously treated as inflammatory lesions.
  • Their clinicopathological aspects, treatment, and poor survival as a consequence of delays in diagnosis are discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16505791.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 15
  •  go-up   go-down


2. Shah JP, Gil Z: Current concepts in management of oral cancer--surgery. Oral Oncol; 2009 Apr-May;45(4-5):394-401
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgery is the most well established mode of initial definitive treatment for a majority of oral cancers.
  • The factors that affect choice of treatment are related to the tumor and the patient.
  • The radial forearm free flap provides excellent soft tissue and lining for soft tissue defects in the oral cavity.
  • Over the course of the past thirty years there has been improvement in the overall survival of patients with oral carcinoma largely due to the improved understanding of the biology of local progression, early identification and treatment of metastatic lymph nodes in the neck, and employment of adjuvant post-operative radiotherapy or chemoradiotherapy.
  • The role of surgery in primary squamous cell carcinomas in other sites in the head and neck has evolved with integration of multidisciplinary treatment approaches employing chemotherapy and radiotherapy either sequentially or concurrently.
  • Advances in skull base surgery have significantly improved the survivorship of patients with malignant tumors of the paranasal sinuses approaching or involving the skull base.
  • Surgery thus remains the mainstay of management of a majority of neoplasms arising in the head and neck area.
  • Similarly, the role of the surgeon is essential throughout the life history of a patient with a malignant neoplasm in the head and neck area, from initial diagnosis through definitive treatment, post-treatment surveillance, management of complications, rehabilitation of the sequelae of treatment, and finally for palliation of symptoms.
  • [MeSH-minor] Antineoplastic Protocols. Bone Neoplasms / surgery. Combined Modality Therapy. Head and Neck Neoplasms / surgery. Humans. Patient Selection. Reconstructive Surgical Procedures. Skin Neoplasms / surgery. Skull Base Neoplasms / surgery. Soft Tissue Neoplasms / surgery. Surgical Flaps. Treatment Outcome


3. Rodrigues TA, Quintela AG, Luz RM, López D: [Thyroid carcinoma with thymus-like differentiation (CASTLE): case report and review of the literature]. Arq Bras Endocrinol Metabol; 2008 Apr;52(3):550-5
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Carcinoma da tireóide com diferenciação semelhante a timo (CASTLE): relato de caso e revisão da literatura.
  • Carcinoma with thymus-like differentiation (CASTLE) is a rare malignant epithelial tumor which arises on soft tissue of the neck or thyroid gland.
  • It is important to differentiate CASTLE from primary or metastatic squamous cell carcinoma of head and neck, and from squamous cell thyroid carcinoma, because it has a different prognosis.
  • CD5 immunoreactivity might be helpful in CASTLE diagnosis.
  • Treatment includes surgical excision and radiotherapy.
  • Chemotherapy can be offered, although its efficacy is not clear.
  • After radiotherapy and chemotherapy, minimal response was obtained.
  • The authors intend to discuss the differential pathologic diagnosis and the best therapy of this indolent but recurrent neoplasm, that demands strict long term follow-up.
  • [MeSH-major] Carcinoma / pathology. Head and Neck Neoplasms / pathology. Thymus Gland / pathology. Thymus Neoplasms / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Squamous Cell / pathology. Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged. Soft Tissue Neoplasms / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18506281.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 20
  •  go-up   go-down


Advertisement
4. Seper L, Schwab R, Kiattavorncharoen S, Büchter A, Bánkfalvi A, Joos U, Piffkó J, Kruse-Loesler B: Malignant fibrous histiocytoma of the face: report of a case. Head Face Med; 2007;3:36
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the face: report of a case.
  • BACKGROUND: Soft tissue sarcomas in the head and neck region are rare and often present a difficult differential diagnosis.
  • The aim of our presentation is to point out the complexity of the diagnosis, treatment and follow up.
  • Four months beforehand, a benign fibrous histiocytoma (BFH) had been removed from the same location by excision biopsy with wide tumour-free resection margins.
  • Excision biopsy of the recurrent lesion revealed a malignant fibrous histiocytoma (MFH).
  • Radical tumour resection was completed by extended parotidectomy and neck dissection; the skin defect was covered by a regional bi-lobed flap.
  • No adjuvant radio- or chemotherapy was administered.
  • DISCUSSION: Malignant transformation of BFH is extremely rare and if so, extended radical surgery may give a fair chance for a favourable outcome even in patients with advanced age.
  • [MeSH-major] Facial Neoplasms / pathology. Facial Neoplasms / surgery. Histiocytoma, Malignant Fibrous / pathology. Histiocytoma, Malignant Fibrous / surgery. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neck Dissection / methods. Neoplasm Staging. Reconstructive Surgical Procedures / methods. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Sep;37(3):212-7 [10971696.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):239-52 [12778019.001]
  • [Cites] Am J Surg Pathol. 1994 Jul;18(7):668-76 [8017561.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • (PMID = 17945018.001).
  • [ISSN] 1746-160X
  • [Journal-full-title] Head & face medicine
  • [ISO-abbreviation] Head Face Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2211745
  •  go-up   go-down


5. Yang XJ, Zheng JW, Zhou Q, Ye WM, Wang YA, Zhu HG, Wang LZ, Zhang ZY: Angiosarcomas of the head and neck: a clinico-immunohistochemical study of 8 consecutive patients. Int J Oral Maxillofac Surg; 2010 Jun;39(6):568-72
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcomas of the head and neck: a clinico-immunohistochemical study of 8 consecutive patients.
  • Angiosarcoma, also known as malignant hemangioendothelioma, is a rare and aggressive malignant vascular tumour arising from endothelial cells, which accounts for approximately 10% of soft tissue sarcomas in the head and neck.
  • Between October 1996 and July 2008, 10 patients were diagnosed with angiosarcomas (AS) in the head and neck region, 8 of whom were included in this study (there were 7 high-grade and 1 low-grade lesions).
  • Six patients were treated surgically with or without postoperative radiotherapy and/or chemotherapy.
  • Two patients had large and extensive lesions that were considered to be inoperable, they were given palliative chemotherapy and/or radiotherapy.
  • Of the 8 patients reviewed in this study, 5 died of local recurrence or distant metastasis with a survival time of 8-19 months, 2 patients are alive with disease and 1 patient is free of disease.
  • The predeliction for local recurrence and distant metastasis and the high-grade characteristics of this tumour seemed to be correlated to the poor prognosis, although the small number of patients prevented statistical analysis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Head and Neck Neoplasms / chemistry. Head and Neck Neoplasms / pathology. Hemangiosarcoma / chemistry. Hemangiosarcoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD31 / analysis. Antigens, CD34 / analysis. Antigens, Neoplasm / analysis. Factor VIII / analysis. Fatal Outcome. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20413272.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 9001-27-8 / Factor VIII
  •  go-up   go-down


6. Bien E, Stachowicz-Stencel T, Balcerska A, Godzinski J, Kazanowska B, Perek-Polnik M, Madziara W, Rybczynska A, Kurylak A, Zalewska-Szewczyk B, Peregud-Pogorzelski J: Angiosarcoma in children - still uncontrollable oncological problem. The report of the Polish Paediatric Rare Tumours Study. Eur J Cancer Care (Engl); 2009 Jul;18(4):411-20
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The report of the Polish Paediatric Rare Tumours StudyAngiosarcoma is a rare, highly malignant vascular neoplasm with little data available on its clinical course and management in children.
  • Ten children with angiosarcoma (M/F: 6/4; aged 2, 3-16 years) registered in Polish Paediatric Rare Tumours and Soft Tissue Sarcomas Studies between 1992 and 2006.
  • Primary tumour exceeded 5 cm in seven patients and affected mainly deep tissues (heart-2, head/neck, bladder, brain, liver and upper limb - one patient each).
  • All patients received supplementing chemotherapy with no response in four.
  • Three of five secondary tumour resections proved complete.
  • Relapsed patients received chemotherapy +/- radiotherapy and surgery (three).
  • The response to chemotherapy is poor and the large number of metastatic recurrences suggests a need for systemic therapy modifications.
  • [MeSH-major] Hemangiosarcoma / pathology. Hemangiosarcoma / therapy. Sarcoma / pathology. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Disease Progression. Humans. Male. Poland / epidemiology. Prognosis. Radiotherapy. Recurrence. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19490008.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. el-Zeftawy H, Heiba SI, Jana S, Rosen G, Salem S, Santiago JF, Abdel-Dayem HM: Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma. Cancer Biother Radiopharm; 2001 Feb;16(1):37-46
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma.
  • AIM OF THE STUDY: To assess the impact of repeated F-18 FDG studies on the management of patients with bone and soft tissue (B&S) sarcomas.
  • MATERIAL AND METHODS: Twenty patients with B&S tissue tumors (11 M and 9 F age 17-72 years) had 52 F-18 FDG Dual Head Coincidence Imaging (DHCI) studies.
  • 7 patients were followed for 6 months to 2 years clinically after removal of the primary tumor.
  • Patient's preparation, F-18 FDG injection and imaging procedure were done according to department protocol.
  • Tumor to background ratios were calculated for all lesions.
  • Follow up studies showed stable disease in 10 patients while 6 patients who showed worsening disease needed to change their chemotherapy.
  • CONCLUSION: Repeated F-18 FDG DHCI examinations proved to have an impact on the clinical management of patients with malignant bone and soft tissue sarcoma.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Metastasis / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Sarcoma / radionuclide imaging. Soft Tissue Neoplasms / radionuclide imaging. Tomography, Emission-Computed
  • [MeSH-minor] Adolescent. Adrenal Gland Neoplasms / radionuclide imaging. Adrenal Gland Neoplasms / secondary. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease Progression. Female. Follow-Up Studies. Humans. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / secondary. Male. Middle Aged. Posture. Retrospective Studies

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11279796.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


8. Wessalowski R, Schneider DT, Mils O, Hannen M, Calaminus G, Engelbrecht V, Pape H, Willers R, Engert J, Harms D, Göbel U: An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin Padiatr; 2003 Nov-Dec;215(6):303-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors.
  • BACKGROUND: Elevated temperatures of 40 - 44 degrees C increase the actions of various anticancer drugs including N-lost derivatives, cytotoxic antibiotics and platinum analoga.
  • In clinical usage thermochemotherapy (TCH) should facilitate surgical resection and ameliorate local tumor control.
  • Among these, 24 patients had extracranial non-testicular germ cell tumors and 15 patients soft tissue or chondrosarcomas.
  • INDICATION: locoregional relapse (n = 29) or unresectable tumor after neoadjuvant chemotherapy (n = 10).
  • Among these two groups, there were ten patients with poor response or progressive disease under primary or relapse chemotherapy.
  • Tumor site: pelvis (30), abdomen (4), head and neck (2), proximal leg (2) and lumbar spine (1).
  • TCH was followed by surgical tumor resection in 28/39 patients and/or radiotherapy in 13/39 patients.
  • CONCLUSION: TCH shows substantial therapeutic efficacy and facilitates complete tumor resection in 14 out of 28 operated patients.
  • Multimodal treatment including TCH, surgical resection and/or radiotherapy leads to sustained remission in the majority of patients with locoregional tumor recurrence.
  • The therapeutic effect is most pronounced, if TCH is administered at first relapse.
  • Therefore, a more valid assessment of treatment efficacy can only be made by a matched-pair comparison in cooperation with the clinical registers.
  • [MeSH-major] Abdominal Neoplasms / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Chondrosarcoma / therapy. Cisplatin / therapeutic use. Etoposide / therapeutic use. Germinoma / therapy. Head and Neck Neoplasms / therapy. Hyperthermia, Induced. Ifosfamide / therapeutic use. Lumbar Vertebrae. Pelvic Neoplasms / therapy. Sarcoma / therapy. Soft Tissue Neoplasms / therapy. Spinal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Chi-Square Distribution. Child. Child, Preschool. Combined Modality Therapy. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Infant. Karnofsky Performance Status. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Time Factors. Treatment Outcome


9. Woźniak AW, Nowaczyk MT, Osmola K, Golusinski W: Malignant transformation of an osteoblastoma of the mandible: case report and review of the literature. Eur Arch Otorhinolaryngol; 2010 Jun;267(6):845-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of an osteoblastoma of the mandible: case report and review of the literature.
  • Benign osteoblastoma is a rarely seen tumor of the facial bones.
  • The authors present a case of a 30-year-old man with a tumor of the mandibular body and ramus.
  • The histopathological diagnosis was one of osteoblastoma.
  • Postoperative recurrence with soft tissue infiltration suggested an osteosarcoma radiologically, but the histological examination again revealed the presence of an osteoblastoma.
  • A second recurrence occured in the pharyngo-glossal region and this time the tumor was histologically diagnosed as an osteoblastoma, but with foci of well-differentiated osteosarcoma.
  • The patient was given a course of radiotherapy, but clinical and radiological examination 8 months later revealed lung metastases and chemotherapy was started.
  • While osteoblastomas are rare, and their sarcomatous change even rarer, our experience with this case lead us to suggest that a therapeutic preventative approach, involving both chemotherapy and total excision of the tumor, is the regime to adopt with osteoblastomas which involve soft tissues and have radiological features suggesting malignancy.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Mandibular Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Osteoblastoma / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Male. Mandible / pathology. Mandible / surgery. Radiography, Panoramic. Radiotherapy, Adjuvant. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Spine J. 1998;7(3):246-8 [9684960.001]
  • [Cites] J Clin Pathol. 1993 Nov;46(11):1024-9 [8254089.001]
  • [Cites] Neurosurg Rev. 1997;20(1):51-4 [9085288.001]
  • [Cites] Histopathology. 1997 Aug;31(2):196-200 [9279574.001]
  • [Cites] Med Pediatr Oncol. 1997 Apr;28(4):305-9 [9078333.001]
  • [Cites] Skeletal Radiol. 1994 Oct;23 (7):509-12 [7824976.001]
  • [Cites] J Neurosurg. 1991 Jul;75(1):138-42 [2045899.001]
  • [Cites] Gen Diagn Pathol. 1996 May;141(5-6):377-92 [8780939.001]
  • [Cites] Eur J Radiol. 1998 May;27 Suppl 1:S91-7 [9652508.001]
  • [Cites] Skeletal Radiol. 1994 Nov;23 (8):656-9 [7886478.001]
  • [Cites] Aktuelle Radiol. 1996 Nov;6(6):338-40 [9081408.001]
  • [Cites] Cancer. 1985 Jan 15;55(2):416-26 [3855268.001]
  • [Cites] J Comput Assist Tomogr. 1996 Jan-Feb;20(1):116-8 [8576460.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):117-34 [8119712.001]
  • [Cites] Chirurg. 2002 Dec;73(12 ):1181-90 [12491047.001]
  • [Cites] Arq Neuropsiquiatr. 1998 Jun;56(2):292-5 [9698743.001]
  • [Cites] J Laryngol Otol. 1997 Sep;111(9):865-8 [9373556.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Jan;52(1):86-90 [8263651.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Feb;18(2):324-6 [9111670.001]
  • [Cites] Surg Neurol. 1998 Mar;49(3):274-7 [9508114.001]
  • (PMID = 20012077.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 20
  •  go-up   go-down


10. Mosca F, Stracqualursi A, Lipari G, Persi A, Latteri S: [Malignant stromal tumors of the duodenum. Report of a case]. Chir Ital; 2000 Nov-Dec;52(6):725-32
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant stromal tumors of the duodenum. Report of a case].
  • The Authors report a rare case of undifferentiated duodenal malignant stromal tumour in a 69-years-old man radically managed by pancreaticoduodenectomy and resection of a liver metastasis.
  • Several preoperative tests were performed (barium meal, endoscopy, ultrasonography and CT scan) but failed to yield a differential diagnosis between a tumour of the pancreatic head and a retroperitoneal neoplasm.
  • The diagnosis was only histological.
  • The tumour was considered to be high-grade due to its large size, high mitotic index, and the presence of necrosis and liver metastasis.
  • Thorough surveillance revealed several hepatic metastases 29 months after resection, and chemotherapy performed at this stage proved completely ineffective.
  • [MeSH-major] Duodenal Neoplasms / pathology. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11200011.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Whatley WS, Thompson JW, Rao B: Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg; 2006 Mar;134(3):385-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There is an increased incidence of second malignant neoplasms in survivors of childhood cancers.
  • The most common second malignancies are acute leukemia, bone and soft tissue tumors, and carcinoma of the skin, breast, and thyroid.
  • Although, ionizing radiation has been demonstrated to increase the risk of developing a salivary gland neoplasm, there are few reports of salivary gland neoplasms occurring in patients treated for cancer in childhood.
  • RESULTS: Twelve survivors of childhood cancer developed a salivary gland neoplasm after completion of treatment.
  • These patients were initially treated for a variety of childhood cancers with a combination of radiation and chemotherapy.
  • All patients were treated with surgical excision of the primary tumor, and postoperative radiation was added in select patients.
  • CONCLUSION: Radiation and chemotherapy used to treat patients with childhood malignancies increases the risk of developing a second neoplasm of salivary gland origin.
  • The majority of these neoplasms are malignant; mucoepidermoid carcinoma occurs most frequently.
  • The treatment of these tumors includes surgical excision of the primary, with neck dissection in patients with clinical evidence of nodal metastasis, and postoperative radiation added for pathologies with adverse features.
  • [MeSH-major] Neoplasms, Second Primary / diagnosis. Salivary Gland Neoplasms / diagnosis. Survivors
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / surgery. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / surgery. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis / diagnosis. Male. Neck Dissection. Neoplasms / drug therapy. Neoplasms / radiotherapy. Radiotherapy, Adjuvant. Registries. Retrospective Studies. Risk Factors


12. Stachowicz-Stencel T, Bień E, Stefanowicz J, Połczytńska K, Sierota D, Szołkiewicz A, Drozyńska E, Kosiak W, Stankiewicz C, Pietniczka M, Kukwa A, Czauderna P, Balcerska A: [Diagnostic and therapeutic difficulties in soft tissue sarcomas localized in nonparameningeal head and neck region--own experiences]. Med Wieku Rozwoj; 2005 Jul-Sep;9(3 Pt 2):487-94
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic and therapeutic difficulties in soft tissue sarcomas localized in nonparameningeal head and neck region--own experiences].
  • INTRODUCTION: Soft tissue sarcomas (MTM) localized within the nonorbital and non-parameningeal head and neck region in children are associated with favourable prognosis.
  • However in our material we have observed many therapeutic failures in this group of patients.
  • The aim of the study was to analyze the reasons for disappointing results of oncological therapy in children with MTM treated between 1992 and 2004.
  • Five patients were diagnosed with rhabdomyosarcoma, four--with non-rhlabdomyosarcoma, including: angiosarcoma, malignant triton tumour, fibrosarcoma and leiomyosarcoma.
  • The first sign of the neoplastic disease in all children was tumour.
  • In as many as five of nine patients initially a false histopathological diagnosis was made based on material obtained from aspiration biopsy of the tumour performed in non-oncological centres.
  • This resulted in a significant delay of the proper diagnosis of malignant disease ranging from 2 to 15 months (mean 7 months).
  • Therapy was conducted according to the schemes: MMT-89, CWS-91, CWS-96 and CWS-2002.
  • Durable complete remission after the first line therapy was obtained in one child only.
  • Six patients developed MTM relapse and two--progression during chemotherapy.
  • Finally five children remain disease-free after treatment termination with follow-up of 1 to 1,5 years.
  • Four of then had microscopically complete delayed resection of the tumour or the relapse.
  • Four patients died of neoplasm recurrence and progression.
  • In three of them the proper diagnosis was delayed significantly and they were diagnosed in the first or even second relapse of the tumour.
  • CONCLUSION: Unfavourable course and treatment results in MTM located in nonorbital and nonparameningeal head and neck region in our patients result from initial wrong histopathological diagnosis and delayed therapy institution.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnosis, Differential. Female. Fibrosarcoma / diagnosis. Fibrosarcoma / therapy. Hemangiosarcoma / diagnosis. Hemangiosarcoma / therapy. Humans. Infant. Leiomyosarcoma / diagnosis. Leiomyosarcoma / therapy. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16719161.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


13. Sturgis EM, Potter BO: Sarcomas of the head and neck region. Curr Opin Oncol; 2003 May;15(3):239-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomas of the head and neck region.
  • PURPOSE OF REVIEW: This review discusses the classification, etiology, diagnosis, evaluation, treatment, and prognosis of sarcoma of the head and neck region.
  • RECENT FINDINGS: Sarcomas account for less than 1% of all malignancies in the United States with only 5 to 15% of these sarcomas occurring in the head and neck region.
  • However, about 1 in 3 pediatric sarcomas will occur in the head and neck region.
  • Pathologic classification is critical to the ultimate treatment and prognosis of sarcoma of the head and neck.
  • Osteosarcoma, rhabdomyosarcoma, malignant fibrous histiocytoma, and angiosarcoma are the most common types of sarcoma to occur in the head and neck region; however, up to 20% of head and neck sarcomas will remain unclassified.
  • Adjuvant chemotherapy is being utilized and/or studied for most high-grade sarcomas and adjuvant radiotherapy is important for disease control in high-grade soft-tissue sarcomas.
  • Prognosis is clearly related to tumor grade and margin status.
  • SUMMARY: Sarcomas of the head and neck region are rare malignancies often without a clear etiology.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Sarcoma / pathology. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Hemangiosarcoma / mortality. Hemangiosarcoma / pathology. Hemangiosarcoma / therapy. Humans. Male. Middle Aged. Neoplasm Staging. Osteosarcoma / mortality. Osteosarcoma / pathology. Osteosarcoma / therapy. Prognosis. Radiotherapy, Adjuvant. Rhabdomyosarcoma / mortality. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Risk Assessment. Surgical Procedures, Operative / methods. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12778019.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 157
  •  go-up   go-down


14. Tejada-Berges T, Granai CO, Gordinier M, Gajewski W: Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev Anticancer Ther; 2002 Apr;2(2):143-50
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer.
  • This, coupled with a small vesicular size, uniquely promotes the localization of Caelyx/Doxil at tumor sites and explains its altered toxicity profile.
  • The FDA and EMEA have approved its use for the treatment of AIDS-related Kaposi's sarcoma and, more recently, for recurrent epithelial ovarian cancer (EOC).
  • Numerous investigations have focused on its use in the treatment of metastatic breast cancer, as well as recurrent squamous cell cervical carcinoma, soft tissue sarcoma, squamous head and neck cancers, prostate cancers and malignant gliomas.
  • Ongoing clinical studies of combination regimens incorporating Caelyx/Doxil will further clarify its role in the treatment of advanced solid tumors.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Doxorubicin / administration & dosage. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Animals. Clinical Trials as Topic / methods. Clinical Trials as Topic / statistics & numerical data. Female. Humans. Neoplasm Recurrence, Local / drug therapy


15. Stark AM, Buhl R, Hugo HH, Mehdorn HM: Malignant peripheral nerve sheath tumours--report of 8 cases and review of the literature. Acta Neurochir (Wien); 2001;143(4):357-63; discussion 363-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumours--report of 8 cases and review of the literature.
  • BACKGROUND: Though Malignant peripheral nerve sheath tumours (MPNST) are a rare entity accounting for 5-10% of soft-tissue sarcomas they are an important differential diagnosis to benign tumours of the peripheral nervous system regarding treatment and prognosis.
  • Two patients suffered from Neurofibromatosis type 1.
  • Paraffin embedded tumour specimens were immunohistochemically stained for S-100, p53 and Ki67/MIB-1.
  • Four tumours were localised at the head & neck region, three were found in the extremities and one tumour was located on the trunk.
  • All of these developed local recurrence with a mean disease free survival time of 10.6 months.
  • During follow up, three patients developed distant metastases located in the lung, liver and subcutaneous tissue.
  • Five out of eight patients died during follow-up with a mean survival time of 11.6 months after diagnosis.
  • The Ki67/MIB-1 proliferation index was detectable in all tumour samples, it differed from 10-30%.
  • INTERPRETATION: MPNST is a rare and fatal diagnosis in neurosurgery with high risk of local recurrence and occurence of distant metastases.
  • Though mulitimodal therapy including surgical resection and adjuvant radiotherapy including brachytherapy is available, the prognosis remains dismal.
  • Modern clinical studies and the development of effective chemotherapy is needed in order to gain control of the disease.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / mortality. Nerve Sheath Neoplasms / mortality. Nerve Sheath Neoplasms / surgery. Spinal Cord Neoplasms / mortality. Spinal Cord Neoplasms / surgery. Thoracic Neoplasms / mortality. Thoracic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11437289.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 5
  •  go-up   go-down


16. Chang RC, Dave SP, Robinson PG: Undifferentiated pleomorphic sarcoma of the parotid gland: a rare pediatric case. Head Neck; 2008 Jul;30(7):970-3
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Undifferentiated pleomorphic sarcoma, or malignant fibrous histiocytoma (MFH) of the head and neck is an uncommon malignancy that is exceedingly rare in the pediatric population.
  • Although MFH was once considered the most common soft tissue sarcoma in adults, recently authors have questioned its existence as a distinct pathologic entity.
  • Diagnosis was fraught with difficulty, typical of this disease.
  • He was treated with a combination of chemotherapy and radiation therapy with a good initial response.
  • Surgical resection is the preferred treatment, but combined chemoradiation may be necessary in the head and neck region.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / pathology. Parotid Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Biopsy, Needle. Child. Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neoplasm Staging. Parotid Gland / surgery. Rare Diseases. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Pleomorphic Undifferentiated Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18098306.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Chigurupati R, Alfatooni A, Myall RW, Hawkins D, Oda D: Orofacial rhabdomyosarcoma in neonates and young children: a review of literature and management of four cases. Oral Oncol; 2002 Jul;38(5):508-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rhabdomyosarcoma (RMS) is an aggressive malignant skeletal muscle neoplasm arising from embryonal mesenchyme.
  • It accounts for over 50% of all pediatric soft tissue sarcomas.
  • The head and neck region is the most common site for this tumor in children.
  • Neonatal presentation of this tumor is rare.
  • Three of the four cases were alveolar RMS and one was botryoid sub-type of embryonal RMS.
  • Three patients were treated with a combination of surgery, chemotherapy and radiation, while the patient with botryoid RMS was treated with surgery and chemotherapy only.
  • We discuss the current management, diagnosis, biological behavior, histopathology, prognosis and survival of head and neck RMS in neonates and young children.
  • [MeSH-major] Facial Neoplasms / therapy. Mouth Neoplasms / therapy. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Child. Combined Modality Therapy. Fatal Outcome. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12110348.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


18. Vasanawala MS, Wang Y, Quon A, Gambhir SS: F-18 fluorodeoxyglucose PET/CT as an imaging tool for staging and restaging cutaneous angiosarcoma of the scalp. Clin Nucl Med; 2006 Sep;31(9):534-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous angiosarcoma of the scalp is a rare highly aggressive malignant tumor that typically afflicts elderly patients and commonly presents with extensive local spread and distant metastasis.
  • It differs from other soft tissue sarcomas in that the size of the lesion at presentation instead of tumor grade is the important prognostic factor.
  • Optimal treatment is yet to be determined.
  • Wide-margin complete excision with postoperative radiotherapy has been the most effective therapy.
  • Chemotherapy and gene therapy have been used with some success.
  • Local extent is critical in surgical planning, especially in the head and face, and is difficult to determine accurately with clinical examination and morphologic imaging tools.
  • PET/CT imaging after chemotherapy and before radiation therapy showed complete resolution of FDG uptake in the scalp and osseous lesions.
  • Evaluation of more cases of this subset of soft tissue sarcoma with FDG PET/CT may suggest a possible role in not only staging angiosarcomas to determine the extent of local as well as distant disease, but also to potentially help determine response to therapy and early recognition of local or distant recurrence.
  • [MeSH-major] Fluorodeoxyglucose F18. Hemangiosarcoma / diagnosis. Hemangiosarcoma / radionuclide imaging. Neoplasm Staging / methods. Positron-Emission Tomography / methods. Radiopharmaceuticals. Scalp / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / radionuclide imaging. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921276.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


19. Sbeity S, Abella A, Arcand P, Quintal MC, Saliba I: Temporal bone rhabdomyosarcoma in children. Int J Pediatr Otorhinolaryngol; 2007 May;71(5):807-14
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Rhabdomyosarcoma is the most frequent soft tissue sarcoma in the pediatric age group.
  • The twofold objective of this study is to illustrate the clinical presentation, management, and prognosis of this malignant striated muscle tumor, and to compare these results with previously reported series.
  • METHODS: A retrospective study was conducted of patients diagnosed and treated for rhabdomyosarcoma of the head and neck at Saint Justine Hospital, a tertiary pediatric center, between 1970 and 2005.
  • A thorough review of medical and surgical charts was performed to obtain demographic, clinical, paraclinical, and therapeutic data, which were subsequently analyzed and compared to published results.
  • RESULTS: Thirty-nine patients with rhabdomyosarcoma of the head and neck region were identified, among which only six children had temporal bone rhabdomyosarcoma.
  • The mean age at the time of diagnosis was 4.15 years.
  • All patients except two received combined chemotherapy and radiotherapy as treatment.
  • CONCLUSION: Rhabdomyosarcoma of the temporal bone is an aggressive tumor that clinically simulates chronic otitis media.
  • A high index of suspicion should be raised in the context of otitis media that is unresponsive to ordinary medical treatment.
  • A biopsy is hence recommended in the presence of polyps in the external auditory canal that are resistant to medical treatment.
  • Early diagnosis and the adoption of multimodal therapy offer the best outcome.
  • [MeSH-minor] Adolescent. Child, Preschool. Chronic Disease. Female. Humans. Male. Neoplasm Staging. Otitis Media / etiology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17346806.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down






Advertisement